The immunomodulator glatiramer acetate influences spinal motoneuron plasticity during the course of multiple sclerosis in an animal model

Brazilian Journal of Medical and Biological Research

Volumn 42, Issue 2, 2009, Pages 179-188

  Marques, K B ^a   Scorisa, J M ^a   Zanon, R ^a   Freria, C M ^a   Santos, L M B ^a   Damasceno, B P ^a   Oliveira, A L R ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Experimental autoimmune encephalomyelitis; Glatirameracetate; Immunomodulator; Motoneuron; Spinal cord; Synapse elimination

Indexed keywords

GLATIRAMER; GLIAL FIBRILLARY ACIDIC PROTEIN; PLACEBO; SYNAPTOPHYSIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL LOSS; CELL ULTRASTRUCTURE; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GLIA CELL; IMMUNOMODULATION; MOTONEURON; MULTIPLE SCLEROSIS; NERVE CELL PLASTICITY; NERVE ENDING; NEUROPROTECTION; NONHUMAN; RAT; REPEATED DRUG DOSE; SPINAL CORD NERVE CELL; SYNAPSE;

ANIMALIA; RATTUS;

EID: 65549138457     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2009000200006     Document Type: Article

References (33)

1. Trapp BD, Bo L, Mork S, Chang A. Pathogenesis of tissue injury in MS lesions. J Neuroimmunol 1999; 98: 49-56.
2. Kornek B, Storch MK, Weissert R, Wallstroem E, Stefferl A, Olsson T, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 2000; 157: 267-276.
3. Kerschensteiner M, Bareyre FM, Buddeberg BS, Merkler D, Stadelmann C, Bruck W, et al. Remodeling of axonal connections contributes to recovery in an animal model of multiple sclerosis. J Exp Med 2004; 200: 1027-1038.
4. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006; 129: 1953-1971.
5. Marques KB, Santos LM, Oliveira AL. Spinal motoneuron synaptic plasticity during the course of an animal model of multiple sclerosis. Eur J Neurosci 2006; 24: 3053-3062.
6. Lassmann H, Bruck W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001; 7: 115-121.
7. Hemmer B, Archelos JJ, Hartung HP. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 2002; 3: 291-301.
8. Cross AH, Stark JL. Humoral immunity in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. Immunol Res 2005; 32: 85-97.
9. Schmidt CS, Zhao J, Chain J, Hepburn D, Gitter B, Sandusky G, et al. Resistance to myelin oligodendrocyte glycoprotein- induced experimental autoimmune encephalomyelitis by death receptor 6-deficient mice. J Immunol 2005; 175: 2286-2292.
10. Ziemssen T, Ziemssen F. The role of the humoral immune system in multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE). Autoimmun Rev 2005; 4: 460-467.
11. Wegner C. Pathological differences in acute inflammatory demyelinating diseases of the central nervous system. Int MS J 2005; 12: 13-19.
12. Merkler D, Boscke R, Schmelting B, Czeh B, Fuchs E, Bruck W, et al. Differential macrophage/microglia activation in neocortical EAE lesions in the marmoset monkey. Brain Pathol 2006; 16: 117-123.
13. Kust B, Mantingh-Otter I, Boddeke E, Copray S. Deficient p75 low-affinity neurotrophin receptor expression does alter the composition of cellular infiltrate in experimental autoimmune encephalomyelitis in C57BL/6 mice. J Neuroimmunol 2006; 174: 92-100.
14. Li XB, Schluesener HJ. Therapeutic effects of cisplatin on rat experimental autoimmune encephalomyelitis. Arch Immunol Ther Exp 2006; 54: 51-53.
15. Liu Y, Liu J, Tetzlaff W, Paty DW, Cynader MS. Biliverdin reductase, a major physiologic cytoprotectant, suppresses experimental autoimmune encephalomyelitis. Free Radic Biol Med 2006; 40: 960-967.
16. Muthian G, Raikwar HP, Rajasingh J, Bright JJ. 1,25 Dihydroxyvitamin-D3 modulates JAK-STAT pathway in IL-12/IFNgamma axis leading to Th1 response in experimental allergic encephalomyelitis. J Neurosci Res 2006; 83: 1299-1309.
17. Vogler S, Pahnke J, Rousset S, Ricquier D, Moch H, Miroux B, et al. Uncoupling protein 2 has protective function during experimental autoimmune encephalomyelitis. Am J Pathol 2006; 168: 1570-1575.
18. Aharoni R, Kayhan B, Eilam R, Sela M, Arnon R. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci U S A 2003; 100: 14157-14162.
19. Gilgun-Sherki Y, Panet H, Holdengreber V, Mosberg-Galili R, Offen D. Axonal damage is reduced following glatiramer acetate treatment in C57/ bl mice with chronic-induced experimental autoimmune encephalomyelitis. Neurosci Res 2003; 47: 201-207.
20. Racke MK, Martin R, McFarland H, Fritz RB. Copolymer-1- induced inhibition of antigen-specific T cell activation: interference with antigen presentation. J Neuroimmunol 1992; 37: 75-84.
21. Teitelbaum D, Milo R, Arnon R, Sela M. Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein. Proc Natl Acad Sci U S A 1992; 89: 137-141.
22. Fridkis-Hareli M, Teitelbaum D, Gurevich E, Pecht I, Brautbar C, Kwon OJ, et al. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells - specificity and promiscuity. Proc Natl Acad Sci U S A 1994; 91: 4872-4876.
23. Teitelbaum D, Sela M, Arnon R. Copolymer 1 from the laboratory to FDA. Isr J Med Sci 1997; 33: 280-284.
24. Kipnis J, Yoles E, Porat Z, Cohen A, Mor F, Sela M, et al. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc Natl Acad Sci U S A 2000; 97: 7446-7451.
25. Schori H, Kipnis J, Yoles E, WoldeMussie E, Ruiz G, Wheeler LA, et al. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc Natl Acad Sci U S A 2001; 98: 3398-3403.
26. Angelov DN, Waibel S, Guntinas-Lichius O, Lenzen M, Neiss WF, Tomov TL, et al. Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2003; 100: 4790-4795.
27. Ziemssen T, Kumpfel T, Klinkert WE, Neuhaus O, Hohlfeld R. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain 2002; 125: 2381-2391.
28. Emirandetti A, Graciele ZR, Sabha M Jr, De Oliveira AL. Astrocyte reactivity influences the number of presynaptic terminals apposed to spinal motoneurons after axotomy. Brain Res 2006; 1095: 35-42.
29. Conradi S, Skoglund S. Observations on the ultrastructure of the initial motor axon segment and dorsal root boutons on the motoneurons in the lumbosacral spinal cord of the cat during postnatal development. Acta Physiol Scand Suppl 1969; 333: 53-76.
30. Dhib-Jalbut S. Glatiramer acetate (Copaxone) therapy for multiple sclerosis. Pharmacol Ther 2003; 98: 245-255.
31. Polman CH, Uitdehaag BM. New and emerging treatment options for multiple sclerosis. Lancet Neurol 2003; 2: 563-566.
32. Hammarberg H, Lidman O, Lundberg C, Eltayeb SY, Gielen AW, Muhallab S, et al. Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells. J Neurosci 2000; 20: 5283-5291.
33. Cullheim S, Wallquist W, Hammarberg H, Linda H, Piehl F, Carlstedt T, et al. Properties of motoneurons underlying their regenerative capacity after axon lesions in the ventral funiculus or at the surface of the spinal cord. Brain Res Brain Res Rev 2002; 40: 309-316.